Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q0RC
|
|||
| Former ID |
DAP001119
|
|||
| Drug Name |
Ethopropazine
|
|||
| Synonyms |
Aethopropropazin; Athapropazine; Athopropazin; Ethapropazine; Ethopromazine; Etopropezina; Fempropazine; Fenpropazina; Isopthazine; Isotazin; Isothazine; Isothiazine; Lysivane; Parcidol; Pardidol; Parfezine; Parkin; Parkisol; Parsidan; Parsidol; Parsitan; Parsotil; Phenopropazine; Phenoprozine; Prodictazin; Prodierazine; Profenamina; Profenamine; Profenaminum; Prophenamine; Prophenaminum; Rochipel; Rocipel; Rodipal; Profenamina [Italian]; RP 3356; SC 2538; SKF 2538; W 483; Parkin (TN); Parsidan (TN); Parsidol(TN); Profenamina [INN-Spanish]; Profenamine (INN); Profenamine [INN:BAN]; Profenaminum [INN-Latin]; N,N-Diethyl-alpha-methyl-10H-phenothiazine-10-ethanamine; N,N-diethyl-1-phenothiazin-10-ylpropan-2-amine; N,N-Diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; 10-(2-Diethylaminopropyl)phenothiazine; 10-[2-(Diethylamino)-1-Propyl]phenothiazine;10-[2-(Diethylamino)-2-methylethyl]phenothiazine; 10-[2-(Diethylamino)propyl]phenothiazine; 2-Diethylamino-1-propyl-N-dibenzoparathiazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1], [2] | |
| Therapeutic Class |
Antiparkinson Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H24N2S
|
|||
| Canonical SMILES |
CCN(CC)C(C)CN1C2=CC=CC=C2SC3=CC=CC=C31
|
|||
| InChI |
1S/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3
|
|||
| InChIKey |
CDOZDBSBBXSXLB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 522-00-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5235096, 8152090, 10525152, 11335236, 11360475, 11363709, 11366271, 11368833, 11371338, 11374354, 11376995, 11455619, 11461447, 11466868, 11467988, 11484783, 11486456, 11488800, 11490245, 11492363, 11494629, 14923459, 29222428, 46507375, 46509734, 47365017, 47365018, 47959566, 48034942, 48110291, 48184832, 48334311, 48415977, 49698862, 50006444, 57244628, 57321707, 77111137, 85209984, 85505762, 87692421, 90341779, 96025112, 103362582, 104303077, 125672985, 126718928, 134338364, 134977403, 137138734
|
|||
| ChEBI ID |
CHEBI:313639
|
|||
| SuperDrug ATC ID |
N04AA05
|
|||
| SuperDrug CAS ID |
cas=000522009
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethopropazine can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.536; p = 0.025). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethopropazine can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.447; p = 0.012). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethopropazine can be metabolized by Odoribacter splanchnicus (log2FC = -0.384; p = 0.01). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethopropazine can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.517; p = 0.003). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ethopropazine can be metabolized by Clostridium sp. (log2FC = -0.555; p = 0.018). | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Ethopropazine hydrochloride (adjusted p-values: 1.62E-05). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Ethopropazine hydrochloride (adjusted p-values: 7.49E-05). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Ethopropazine hydrochloride (adjusted p-values: 4.38E-04). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Ethopropazine hydrochloride (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Ethopropazine hydrochloride (adjusted p-values: 3.27E-05). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Ethopropazine hydrochloride (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Ethopropazine hydrochloride (adjusted p-values: 2.37E-06). | |||
|
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides xylanisolvens was decreased by Ethopropazine hydrochloride (adjusted p-values: 1.14E-05). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Ethopropazine hydrochloride (adjusted p-values: 1.11E-05). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Ethopropazine hydrochloride (adjusted p-values: 6.55E-07). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Ethopropazine hydrochloride (adjusted p-values: 4.93E-07). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Modulator | [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7181). | |||
| REF 2 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.